Trials / Completed
CompletedNCT01489748
Canadian Avonex PEN Productivity Study
An Open-Label, Observational, Multicenter Study to Evaluate the Impact of AVONEX PEN Autoinjector Therapy on Work Capacity of Multiple Sclerosis Patients in Canada
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 111 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This study is primarily designed to evaluate the impact of AVONEX PEN autoinjector on work capacity of participants with multiple sclerosis (MS) starting on this device. This study will also evaluate as secondary endpoints various patient-reported outcomes over the short-term (1 month), including adherence, treatment satisfaction and convenience, and the long-term (12 and 24 months), including adherence, persistence, quality of life (QOL), treatment satisfaction and convenience. It will also assess health resource utilization by MS participants starting on AVONEX PEN autoinjector, as well as overall safety/tolerability, and will correlate all secondary outcomes with the primary (i.e., work capacity).
Conditions
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2014-10-01
- Completion
- 2014-12-01
- First posted
- 2011-12-12
- Last updated
- 2015-02-20
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01489748. Inclusion in this directory is not an endorsement.